Stock Taper
Immuneering Corporation, based in Cambridge, MA, develops oncology and neuroscience therapies, including dual-MEK inhibitors like IMM-1-104 for cancers with RAS/RAF mutations, with additional discovery-stage programs targeting MAPK and mTOR pathways.

Atebimetinib is an oral MEK inhibitor and Immuneering's lead candidate in Phase 3 for pancreatic cancer, aiming to improve durability and tolerability in treating MAPK pathway-driven tumors.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
ASMB | $34.07 | COMPARE |
ZURA | $5.72 | COMPARE |
ARCT | $15.19 | COMPARE |
ENTA | $13.60 | COMPARE |
FHTX | $6.00 | COMPARE |
TRDA | $7.00 | COMPARE |
PYXS | $3.23 | COMPARE |
TNYA | $0.69 | COMPARE |